Shunichi Kashida
Company: xFOREST Therapeutics Co. Ltd.
Job title: Co-Founder, Representative Director, President & Chief Executive Officer
Bio:
Shunnichi Kashida is a pioneer in RNA-targeted small molecule drug discovery and co-founder/CEO of xFOREST Therapeutics. With a PhD in RNA structural biology and synthetic biology from Kyoto University, he developed high-throughput RNA interaction profiling systems and conducted biophysical RNA research (including RNA localization and RNP LLPS formation) in Paris. In 2020, he co-founded xFOREST in Kyoto with Kaoru Komatsu (CTO) to build an RNA-library-based multiplex discovery platform. As CEO, he leads collaborations with Japan’s top pharmaceutical companies and national grant programs to advance next-generation RNA-targeted therapeutics.
Seminars:
Panel Discussion Increasing Chemical Diversity in RNA-Targeted Splice Modulator Small Molecules to Expand the Target Space & Address Previously Undruggable Diseases 1:00 pm
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas • What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space • Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic…Read more
day: Conference Day One
Breaking the Dimensional Limits of RNA–Ligand Discovery: High- Throughput Insights into Structure, Selectivity, & Function 2:00 pm
• Characterizing RNA motifs with both ligandable pockets & functional elements to improve druggability & achieve mechanism-based targeting • High-resolution quantification of RNA–ligand binding enables SAR-guided optimization from submicromolar hits to nanomolar binders • Interaction big data-driven delineation of novel chemical space to inform future design of selective drug-like RNA bindersRead more
day: Conference Day One